Budget Impact di afatinib per il trattamento in prima linea del Non Small Cell Lung Cancer (NSCLC) con mutazioni non comuni EGFR

BACKGROUND: The current clinical practice for patients affected by Non-Small Cell Lung Cancer (NSCLC) with uncommon mutation is based on afatinib and osimertinib, second and third generation of Tyrosine Kinase Inhibitor (TKI) respectively. For uncommon EGFR mutations, it is still unclear which EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Pompilio, Giuseppe, Morabito, Alessandro, Cortinovis, Diego L., Integlia, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768614/
https://www.ncbi.nlm.nih.gov/pubmed/36628318
http://dx.doi.org/10.33393/grhta.2022.2351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768614/
https://www.ncbi.nlm.nih.gov/pubmed/36628318
http://dx.doi.org/10.33393/grhta.2022.2351

Ejemplares similares